Fmr LLC

recently disclosed that they own 9.3% of Akorn, Inc. (NASDAQ:AKRX) in a Form 13G disclosure that was filed with the Securities and Exchange Commission (SEC) on Tuesday, February 13th. The investor owns 11,618,549 shares of the stock worth approximately $370,631,713. The disclosure is available through the SEC website at this hyperlink.

A number of other institutional investors have also recently made changes to their positions in AKRX. Aperio Group LLC boosted its position in shares of Akorn by 12.4% during the third quarter. Aperio Group LLC now owns 27,867 shares of the company’s stock worth $925,000 after buying an additional 3,076 shares during the period. Ameriprise Financial Inc. boosted its position in shares of Akorn by 26.2% during the third quarter. Ameriprise Financial Inc. now owns 332,030 shares of the company’s stock worth $11,019,000 after buying an additional 68,844 shares during the period. Crossmark Global Holdings Inc. acquired a new position in shares of Akorn during the third quarter worth approximately $597,000. Dimensional Fund Advisors LP boosted its position in shares of Akorn by 2.4% during the second quarter. Dimensional Fund Advisors LP now owns 1,169,587 shares of the company’s stock worth $39,228,000 after buying an additional 27,520 shares during the period. Finally, Cornerstone Capital Management Holdings LLC. boosted its position in shares of Akorn by 1,277.6% during the third quarter. Cornerstone Capital Management Holdings LLC. now owns 331,214 shares of the company’s stock worth $10,992,000 after buying an additional 307,171 shares during the period. 73.11% of the stock is owned by hedge funds and other institutional investors.

Akorn, Inc. (NASDAQ:AKRX) traded down $0.22 during midday trading on Tuesday, hitting $31.90. The company’s stock had a trading volume of 918,900 shares, compared to its average volume of 1,360,057. The company has a market capitalization of $4,017.27, a PE ratio of 32.22, a P/E/G ratio of 1.65 and a beta of 1.33. Akorn, Inc. has a 52 week low of $20.00 and a 52 week high of $34.00. The company has a debt-to-equity ratio of 0.92, a current ratio of 4.16 and a quick ratio of 3.17.

In other Akorn news, Director Brian Tambi sold 15,100 shares of the company’s stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $33.35, for a total value of $503,585.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder John N. Kapoor sold 13,629 shares of the company’s stock in a transaction on Thursday, January 25th. The shares were sold at an average price of $32.67, for a total value of $445,259.43. The disclosure for this sale can be found here. 28.20% of the stock is currently owned by corporate insiders.

Several equities analysts have recently issued reports on AKRX shares. Jefferies Group set a $34.00 price objective on Akorn and gave the stock a “hold” rating in a research report on Sunday, October 29th. Zacks Investment Research upgraded Akorn from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 24th. Piper Jaffray Companies set a $34.00 price objective on Akorn and gave the stock a “hold” rating in a research report on Sunday, October 22nd. Finally, BidaskClub upgraded Akorn from a “strong sell” rating to a “sell” rating in a research report on Thursday, January 11th. Three equities research analysts have rated the stock with a sell rating and eight have assigned a hold rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $29.17.

TRADEMARK VIOLATION NOTICE: This story was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://theolympiareport.com/2018/02/13/akorn-inc-akrx-stake-owned-by-fmr-llc.html.

About Akorn

Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.

Want to see what other hedge funds are holding AKRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Akorn, Inc. (NASDAQ:AKRX).

Institutional Ownership by Quarter for Akorn (NASDAQ:AKRX)

Receive News & Ratings for Akorn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn and related companies with MarketBeat.com's FREE daily email newsletter.